Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research Associates

Neither a doctor nor a teaching hospital

Research payments

$4,525,746

407 payments

Through program year 2025, Advanced Research Associates is reported as receiving $4,525,746 in research payments, across 407 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$178,012	29
2024	Research	$255,012	28
2023	Research	$401,356	21
2022	Research	$1,025,848	47
2021	Research	$667,086	110
2020	Research	$734,174	72
2019	Research	$1,264,258	100

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $2,063,359 138 payments
Allergan Inc. $1,638,930 83 payments
Ventana Medical Systems, Inc. $361,873 23 payments
Aclaris Therapeutics, Inc. $137,810 20 payments
Sebela Pharmaceuticals Inc. $119,373 22 payments
GlaxoSmithKline, LLC. $117,610 71 payments
Exeltis, USA Inc. $35,885 33 payments
Endo Pharmaceuticals Inc. $31,207 11 payments
Novartis Pharmaceuticals Corporation $8,448 1 payment
Pfizer Inc. $7,245 3 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $1,088,577 22 payments
Ph 3 Open-label Extension Study $411,481 13 payments
Rd003109 $361,873 23 payments
Ph 3 Open-label Extension Study $352,774 14 payments
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $248,385 11 payments
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $223,275 22 payments
Ph 3 Pivotal GL and GLLCL - USEU $205,052 6 payments
Ph 3 Pivotal GL and GL+LCL - US/EU $143,730 13 payments
Mt10109l in the Treatment of Glabellar Lines With Or Without Concurrent Treatment of Lateral Canthal Lines $142,035 5 payments
Ph 3 Pivotal LCL Only - USEU $139,639 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.